These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 37805439)
1. [Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)]. ; Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):717-740. PubMed ID: 37805439 [TBL] [Abstract][Full Text] [Related]
2. [Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition)]. ; Zhonghua Zhong Liu Za Zhi; 2022 Oct; 44(10):1047-1065. PubMed ID: 36319450 [TBL] [Abstract][Full Text] [Related]
3. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations]. Ma SX; Ma N; Han J; He Z; Wang L; Wang Q Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963 [No Abstract] [Full Text] [Related]
4. [Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations]. Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology Zhongguo Fei Ai Za Zhi; 2024 Feb; 27(2):81-87. PubMed ID: 38453438 [TBL] [Abstract][Full Text] [Related]
5. [Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2020 Version)]. Zhou C; Wang J; Wang B; Cheng Y; Wang Z; Han B; Lu Y; Wu G; Zhang L; Song Y; Zhu B; Hu Y; Wang Z; Song Q; Ren S; He Y; Hu X; Zhang J; Yao Y; Zhao H; Wang Z; Chu Q; Duan J; Liu J; Qin S Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):217-235. PubMed ID: 33896153 [TBL] [Abstract][Full Text] [Related]
6. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405 [No Abstract] [Full Text] [Related]
7. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations. Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602 [TBL] [Abstract][Full Text] [Related]
9. [Chinese expert consensus on evaluation and treatment of advanced non-small cell lung cancer with negative driver genes after first-line immunotherapy resistance (2024 edition)]. Committee of Non-Small Cell Lung Cancer of Chinese Society of Clinical Oncology Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(6):411-426. PubMed ID: 38326053 [TBL] [Abstract][Full Text] [Related]
10. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Shea M; Costa DB; Rangachari D Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer. Chen Y; Chen Z; Chen R; Fang C; Zhang C; Ji M; Yang X Future Oncol; 2022 May; 18(14):1757-1775. PubMed ID: 35232247 [TBL] [Abstract][Full Text] [Related]
12. [Chinese expert consensus on the diagnosis and treatment of advanced RET fusion-positive non-small cell lung cancer (2023 edition)]. ; ; Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):991-1002. PubMed ID: 38110308 [TBL] [Abstract][Full Text] [Related]
13. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations. Ahn MJ; Mendoza MJL; Pavlakis N; Kato T; Soo RA; Kim DW; Liam CK; Hsia TC; Lee CK; Reungwetwattana T; Geater S; Chan OSH; Prasongsook N; Solomon BJ; Nguyen TTH; Kozuki T; Yang JC; Wu YL; Mok TSK; Tan DS; Yatabe Y Clin Lung Cancer; 2022 Dec; 23(8):670-685. PubMed ID: 36151006 [TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions. Zhong J; Bai H; Wang Z; Duan J; Zhuang W; Wang D; Wan R; Xu J; Fei K; Ma Z; Zhang X; Wang J Front Med; 2023 Feb; 17(1):18-42. PubMed ID: 36848029 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. Shi C; Wang Y; Xue J; Zhou X Front Immunol; 2022; 13():940288. PubMed ID: 35935943 [TBL] [Abstract][Full Text] [Related]
16. The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer. Shen Z; Teng M; Han L; Bian D; Zhang J; Zhu X; Qing Y; Hu S; Chen Y; Yao W; Yu H; Zhang L; Zhang P Cancer Immunol Immunother; 2023 Dec; 72(12):4235-4247. PubMed ID: 37932425 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S Front Immunol; 2022; 13():974581. PubMed ID: 36159860 [TBL] [Abstract][Full Text] [Related]
18. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases. Mayenga M; Assié JB; Monnet I; Massiani MA; Tabeze L; Friard S; Fraboulet S; Métivier AC; Chouaïd C; Zemoura L; Longchampt E; Callens C; Melaabi S; Couderc LJ; Doubre H Lung Cancer; 2020 Dec; 150():21-25. PubMed ID: 33045465 [TBL] [Abstract][Full Text] [Related]
19. To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations. Cai R; Zhu H; Liu Y; Sha H; Peng W; Yin R; Zhou G; Fang Y J Cancer Res Clin Oncol; 2023 Sep; 149(12):10027-10040. PubMed ID: 37261523 [TBL] [Abstract][Full Text] [Related]
20. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]